Explore Stanford technologies available for licensing:

Stanford researchers have developed a targeted antisense oligonucleotide (ASO) platform to restore physiological regulation of DYRK1A, a key driver of neurodevelopmental and neurodegenerative pathology in Down syndrome (Trisomy 21) and other tauopathies.

Stanford researchers have developed a fast and flexible platform for building human brain organoids that mimic the complexity of the brain's cellular makeup. This breakthrough enables faster research and better disease modeling for neurological conditions.